| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Journal of Korean Neurosurgical Society > Volume 46(6); 2009 > Article
Journal of Korean Neurosurgical Society 2009;46(6): 552-557.
doi: https://doi.org/10.3340/jkns.2009.46.6.552
Inhibitory Effect of IFN-beta, on the Antitumor Activity of Celecoxib in U87 Glioma Model.
Eun Kyoung Kim, Dong Sup Chung, Hye jin Shin, Yong Kil Hong
1Department of Neurosurgery, The Catholic University of Korea College of Medicine, Kangnam St. Mary's Hospital, Seoul, Korea. hongyk@cotholic.ac.kr
2The Catholic University of Korea College of Medicine, Kangnam St. Mary's Hospital, Seoul, Korea.
3Department of Neurosurgery, The Catholic University of Korea College of Medicine, Incheon St. Mary's Hospital, Incheon, Korea.
ABSTRACT
OBJECTIVE
Interferon-beta, (IFN-beta) has been used in the treatment of cancers. Inhibition of the enzyme cyclooxygenase (COX) with celecoxib had a significantly suppressive effect on tumor growth, angiogenesis, and metastasis in a variety of tumors. The aim of this study was to elucidate the antiglioma effect of combined treatment with IFN-beta and celecoxib in U87 glioma model. METHODS: The in vitro effects of IFN-beta (50-1,000 IU/mL) and celecoxib (50-250 micrometer) alone or combination of both on the proliferation and apoptosis of U87 cells were tested using MTT assay, FACS analysis and DNA condensation. To determine the in vivo effect, nude mice bearing intracerebral U87 xenograft inoculation were treated with IFN-beta intraperitoneally (2x10(5) IU/day for 15 days), celecoxib orally (5, 10 mg/kg) or their combination.
RESULTS
IFN-beta or celecoxib showed an inhibitory effect on the proliferation of U87 cells. When U87 cells were treated with IFN-beta and celecoxib combination, it seemed that IFN-beta interrupted the antiproliferative and apoptotic activity of celecoxib. No additive effect was observed on the survival of the tumor bearing mice by the combination of IFN-beta and celecoxib. CONCLUSION: These results suggest that IFN-beta seems to inhibit the antiglioma effect of celecoxib, therefore combination of IFN-beta and celecoxib may be undesirable in the treatment of glioma.
Key Words: Celecoxib; Cyclooxygenase-2 inhibitor; Glioma; Interferon-beta
Editorial Office
1F, 18, Heolleung-ro 569-gil, Gangnam-gu, Seoul, Republic of Korea
TEL: +82-2-525-7552   FAX: +82-2-525-7554   E-mail: kns61@neurosurgery.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Neurosurgical Society.                 Developed in M2PI
Close layer
prev next